Working… Menu

Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03161366
Recruitment Status : Completed
First Posted : May 19, 2017
Last Update Posted : December 19, 2018
Medecins Sans Frontieres, Netherlands
Information provided by (Responsible Party):

Brief Summary:
Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disease.

Condition or disease Intervention/treatment Phase
Ebola Virus Disease Biological: rVSVΔG-ZEBOV-GP Phase 3

Detailed Description:

Ebola Virus Disease remains ill-known by populations, creating fear and mistrust, is highly contagious, requiring strict isolation measures and with only supportive therapy available that has limited impact on case-fatality which remains high (30 -80%).1 Among vaccines in development, the rVSVΔG-ZEBOV-GP vaccine has given the most promising results in terms of efficacy and safety having been evaluated now in more than 10,000 individuals.

Ring vaccination is a known strategy to control epidemics with specific transmission chains and has been successfully implemented to eradicate smallpox. Ring vaccination enhances standard public health measures of contact tracing, isolation, and community engagement and could be effective when such measures are in place. Building on the interim results of the Ebola ça Suffit trial, there is a need for continued access to a vaccine of which available results suggest that it is safe and likely efficacious against EVD. Although only isolated cases have been reported in Guinea, Sierra Leone and Liberia in 2016, 10 the risk of resurgence or of continued isolated cases in West Africa remains. Moreover, a new outbreak with Ebola Zaïre could start any moment in any of the countries where previous outbreaks occurred as in for example Democratic Republic of Congo and Uganda.

However, the unusual design of the ring trial and the decision to abandon the control group because of strong evidence that the vaccine prevented disease means there may not be enough data to ensure approval from regulatory agencies. Therefore, additional information is still required to consolidate knowledge on the rVSVΔG-ZEBOV-GP vaccine to support regulatory approval and licensure for future access. Additional information is also needed on ring vaccination and contextual adaptations to this approach to ensure its feasibility and effectiveness in the control of Ebola outbreaks in potentially diverse contexts.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 500 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Interventional, single arm, open-label, non-randomized
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP
Actual Study Start Date : May 28, 2018
Actual Primary Completion Date : July 14, 2018
Actual Study Completion Date : November 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ebola

Arm Intervention/treatment
Experimental: Single arm
Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
Biological: rVSVΔG-ZEBOV-GP
Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case

Primary Outcome Measures :
  1. Cumulative incidence [ Time Frame: 84 days after vaccination ]
    Occurrence of Ebola Zaire cases amongst contacts and contacts of contacts

Secondary Outcome Measures :
  1. Assessment of Adverse and Serious Adverse Events [ Time Frame: 84 days after vaccination ]
    Safety of a single dose of rVSVΔG-ZEBOV-GP

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Individuals aged 6 years or older will be enrolled in the study if they are a contact or contact of contact of a laboratory-confirmed Ebola virus disease case. Children aged between 1 and 6 years may also be enrolled in the study in case there is a confirmed contact with a laboratory-confirmed Ebola patient
  • willing to accept weekly visits
  • intending to remain in the study area for three months
  • providing informed consent, and where applicable, assent

Exclusion Criteria:

  • history of EVD (self-report or laboratory confirmed)
  • history of having received other investigational research agents in the previous 28 days
  • history of anaphylaxis to a vaccine or vaccine component (self-report)
  • severe illness that makes the person bed-bound or requiring hospitalization at the time of the vaccination
  • severe immunocompromised status
  • history of having received immunosuppressant therapies that would substantially interfere with the mode of action of the Ebola vaccine in the previous 6 months
  • unwilling to accept weekly visits
  • not intending to remain in the study area for three months
  • informed consent or assent not provided
  • any other condition in which, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, or impair the subject or caregiver's ability to give informed consent, and where applicable, assent.
  • fever above 38°C
  • previous receipt of rVSVΔG-ZEBOV-GP in the last 3 years or at being part of another Ebola vaccine clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03161366

Layout table for location information
Congo, The Democratic Republic of the
Médecins Sans Frontières
Kinshasa, Congo, The Democratic Republic of the
Mbarara, Uganda, 1956
Sponsors and Collaborators
Medecins Sans Frontieres, Netherlands
Layout table for additonal information
Responsible Party: Epicentre Identifier: NCT03161366    
Other Study ID Numbers: V920-01
First Posted: May 19, 2017    Key Record Dates
Last Update Posted: December 19, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: To be done following MSFdata sharing policy

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Epicentre:
Ebola Zaire Outbreak
Safety of rVSVΔG-ZEBOV-GP vaccine
Effectiveness of rVSVΔG-ZEBOV-GP vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases
Hemorrhagic Fever, Ebola
Hemorrhagic Fevers, Viral
RNA Virus Infections
Filoviridae Infections
Mononegavirales Infections